inflammation in experimental models of alzheimer’s disease ...sunnyvale, ca) in human sk-n-sh...
TRANSCRIPT
Small molecule modulator of sigma 2 receptor is neuroprotective and reduces cognitive deficits and neuro-inflammation in experimental models of Alzheimer’s disease
Bitna Yia,#, James J. Sahnb,#, Pooneh Memar Ardestania,#, Andrew K. Evansa, Luisa Scottc, Jessica Z. Chanb, Sangeetha Iyerc, Ashley Crispc, Gabriella Zunigac, Jonathan Pierce-Shimomurac, Stephen F. Martinb, and Mehrdad Shamlooa
aStanford University School of Medicine, Department of Neurosurgery, 1050 Arastradero Road, Building A, Palo Alto, CA 94304
bDepartment of Chemistry, The University of Texas at Austin, 105 E. 24th Street, Stop A5300, Austin, TX 78712, USA
cWaggoner Center for Alcohol and Addiction Research, Institute of Neuroscience, Center for Learning and Memory, Center for Brain, Behavior, and Evolution, and Department of Neuroscience, The University of Texas at Austin, Texas 78712
Abstract
Accumulating evidence suggests that modulating the sigma 2 receptor (Sig2R) can provide
beneficial effects for neurodegenerative diseases. Herein, we report the identification of a novel
class of Sig2R binding ligands and their cellular and in vivo activity in experimental models of
Alzheimer’s disease (AD). We report that SAS-0132 and DKR-1051, selective ligands of Sig2R,
modulate intracellular Ca2+ levels in human SK-N-SH neuroblastoma cells. The Sig2R antagonists
SAS-0132 and JVW-1009 are neuroprotective in a C. elegans model of amyloid precursor protein-
mediated neurodegeneration. Since this neuroprotective effect is replicated by genetic knockdown
and knockout of vem-1, the ortholog of progesterone receptor membrane component-1
(PGRMC1), it indicates that Sig2R ligands modulate a PGRMC1-related pathway. Last, we
demonstrate that SAS-0132 improves cognitive performance both in the Thy-1 hAPPLond/Swe+
transgenic mouse model of AD and in healthy wild-type mice. These results demonstrate that
Sig2R is a promising therapeutic target for neurocognitive disorders including AD.
Keywords
Alzheimer’s disease; AD; sigma 1 receptor; Sig1R; sigma 2 receptor; Sig2R; progesterone receptor membrane component-1; PGRMC1
*Corresponding Author: Mehrdad Shamloo, Stanford University School of Medicine, Department of Neurosurgery, 1050 Arastradero Road, Building A, Palo Alto, CA 94304. Tel: (650) 725-3152; Fax: (650) 723-4147; [email protected].#Indication of co-first author status
DisclosuresThe authors have no conflicts of interest to declare.
HHS Public AccessAuthor manuscriptJ Neurochem. Author manuscript; available in PMC 2017 February 16.
Published in final edited form as:J Neurochem. 2017 February ; 140(4): 561–575. doi:10.1111/jnc.13917.
Author M
anuscriptA
uthor Manuscript
Author M
anuscriptA
uthor Manuscript
INTRODUCTION
Alzheimer’s disease (AD) is currently the sixth leading cause of death in the US (Reitz &
Mayeux 2014, James et al. 2014). The hallmarks of AD include neuronal loss,
neuroinflammation, and the accumulation of amyloid plaques and neurofibrillary tangles
(Mattson 2004, Citron 2010, Huang & Mucke 2012). The multifaceted pathology of AD
makes it difficult to develop effective treatments. Current therapies for AD rely upon
transiently mitigating some of its symptoms. However, these medications do not alter
pathology underlying the disease (Cummings et al. 2014), and there remains an unmet need
for therapeutic approaches to treat AD.
It is notable that modulating sigma receptors, for which the two known subtypes are sigma 1
(Sig1R) and sigma 2 (Sig2R) (Nguyen et al. 2014a, Matsumoto et al. 2007), has only
recently been explored as a possible strategy for treating neurological disorders. Both sigma
receptor subtypes are expressed in the central nervous system (CNS) and distinguished from
one another based upon their affinity for different ligands and biological profiles. Sig1Rs,
which have been cloned, are chaperone proteins that reside in the endoplasmic reticulum-
mitochondrion interface as well as in nuclear and plasma membranes (Su et al. 2010,
Hashimoto 2013, Su et al. 2016); the structure of a trimer of Sig1R has been characterized
by X-ray crystallography (Schmidt et al. 2016). Although Sig2Rs have not been cloned, they
are widely distributed in the CNS and are implicated in cellular processes relevant to cancer
and CNS disorders (Bowen 2000, Mach et al. 2013, Huang et al. 2014, Guo & Zhen 2015).
Recent photo affinity and fluorescent-probe experiments suggest that the putative Sig2R
binding site is the progesterone receptor membrane component-1(PGRMC1) protein
complex (Xu et al. 2011). PGRMC1 is a cytochrome-like single-transmembrane protein that
has been structurally characterized as a heme-bound dimer (Kabe et al. 2016) and is
involved in neuroprotection and axonal migration (Rohe et al. 2009, Runko & Kaprielian
2004, Cahill 2007). However, other reports conclude PGRMC1 and Sig2R are distinct
molecular entities (Abate et al. 2015, Chu et al. 2015). These two views are not necessarily
mutually exclusive, and further work is needed to resolve this issue. Notwithstanding this
controversy, we originally identified the compounds described herein as Sig2R binding
ligands and found they modulate a PGRMC1-related pathway, thus we will refer to the
biological target by the descriptor Sig2R/PGRMC1.
We became interested in Sig2R/PGRMC1 several years ago as a possible target for drug
discovery in neurodegenerative diseases because of its widespread occurrence in the CNS
and its putative involvement in calcium homeostasis. Within the CNS, Sig2R/PGRMC1 is
highly expressed in the cortex and hippocampus, two regions known to be important for
cognitive function (Izzo et al. 2014b, French & Pavlidis 2011). Moreover, Sig2R/PGRMC1
signaling has been implicated in cellular processes relevant to CNS diseases, including
neuroprotection, axonal migration, and mitochondrial protection (Cahill 2007, Qin et al. 2015). For example, progesterone, which binds to both Sig2R and PGRMC1 (Chu et al. 2015), exerts neurogenic and neuroprotective effects in neural progenitor cells derived from
adult rat brain (Liu et al. 2009). In the context of AD-related pathology, afobazole, which is
a pan-selective Sig1R-Sig2R ligand, reduces neurotoxic microglia stimulation and apoptosis
induced by fragments of amyloid beta (Aβ) (Behensky et al. 2013). Recent work conducted
Yi et al. Page 2
J Neurochem. Author manuscript; available in PMC 2017 February 16.
Author M
anuscriptA
uthor Manuscript
Author M
anuscriptA
uthor Manuscript
by Cognition Therapeutics also show that Aβ oligomers are Sig2R/PGRMC1 ligands and
that blocking the binding of these oligomers to Sig2R/PGRMC1 mitigates the synaptotoxic
effects of Aβ oligomers (Izzo et al. 2014a, Izzo et al. 2014b). Moreover, exposure of
cultured neurons to Aβ oligomers produces progressive upregulation of Sig2R/PGRMC1
(Izzo et al. 2014b). This study also revealed that density of Sig2R/PGRMC1 remains
unchanged in severely demented AD patients compared to the age-matched normal
individuals despite a high degree of cell loss, suggesting that Sig2R/PGRMC1 may be
upregulated in AD patients. These findings suggest Sig2R/PGRMC1 is involved in AD
pathology. Thus, we hypothesized that ligands that modulate Sig2R/PGRMC1 may hold
significant promise as medicinal agents to treat AD.
As part of a broad effort to identify novel compounds with possible applications in
neuroscience (Sahn et al. 2014, Martin 2013), we screened collections of substituted
heterocyclic compounds against a variety of CNS proteins in the Psychoactive Drug
Screening Program (PDSP) (Besnard et al. 2012). We thus identified a subclass of
substituted norbenzomorphans that bind to Sig2R with high affinity (Sahn & Martin 2012,
Sahn et al. 2016). This is an important discovery because norbenzomorphans have compact
molecular scaffolds and may be easily modified for structure-activity-relationship studies.
Moreover, they are structurally distinct from all other known Sig2R binding ligands (Mach,
Zeng, and Hawkins 2013; Huang et al. 2014; Guo and Zhen 2015). Of the initial set of
compounds, SAS-0132 emerged as an attractive candidate for further study because it
exhibits 9-fold selectivity for Sig2R over Sig1R, and has low off-target affinity for most
other CNS-relevant targets. With this newly identified Sig2R/PGRMC1 ligand in our hands
as a pharmacological tool, we tested our hypothesis that modulation of Sig2R/PGRMC1
might lead to beneficial effects in the treatment of AD.
Here, we report that the Sig2R/PGRMC1 antagonist SAS-132 produces neuroprotective,
cognitive enhancing, and anti-inflammatory effects in animal models of neurodegeneration.
These results suggest that Sig2R/PGRMC1 represents a promising target to treat
neurodegenerative diseases.
MATERIALS AND METHODS
Intracellular calcium assay
Calcium responses were measured using a Calcium 6-QF assay kit (Molecular Devices,
Sunnyvale, CA) in human SK-N-SH neuroblastoma cells as described in the Appendix
supplemental information. Effects of DKR-1051 or SAS-0132 were tested at final
concentrations of 0.3, 3, 10, 30, or 100 µM. Effects of SAS-0132 on the calcium response
induced by DKR-1051 (100 µM) were tested at final concentrations of 0.1, 0.3, 3, 10, or 30
µM.
C. elegans strains, maintenance, and transgenesis
C. elegans were grown and maintained according to the standard method (Brenner 1974).
Transgenic animals were generated through the MOSSCI technique as previously described
Yi et al. Page 3
J Neurochem. Author manuscript; available in PMC 2017 February 16.
Author M
anuscriptA
uthor Manuscript
Author M
anuscriptA
uthor Manuscript
(Frokjaer-Jensen et al. 2008). Details are described in the Appendix supplemental
information.
C. elegans pharmacological and RNAi treatments
For pharmacological treatment alone, plates contained either vehicle or compound dissolved
in DMSO (final concentration of 200 µM and 0.2% DMSO). For pharmacological and RNAi
co-treatment, the vem-1 (C. elegans homolog of PGRMC1) RNAi colony was selected from
the Ahringer library (Genesequence) and grown overnight in LB with 50 µg/mL of
carbenicillin. After 24 h, this culture was seeded onto carbenicllin-containing NGM-agar
plates with or without 1 mM isopropylthiogalactoside (IPTG) for RNAi treatment. These
plates also contained either vehicle or the Sig2R/PGRMC1 ligands dissolved in DMSO
(final concentration of 200 µM and 0.2% DMSO). Plates that contained vehicle but did not
contain IPTG were considered as sham control plates. The RNAi bacteria were induced
overnight at room temperature for dsRNA expression.
C. elegans neurotoxicity assay
Well-fed, age-synchronized larvae 4 (L4) were picked onto seeded plates with the sterility
compound FUdR (0.12 mM) to prevent progeny from hatching. Larvae were then allowed to
age at 20°C on seeded plates for ~24 h (D1 adult), ~72 h (D3 adult) or ~116 h (D5 adult) to
assess age-related neurodegeneration. Animals were immobilized on 2% agar pads and
scored for neuronal health at 40× within 1 h of 0.7 mM sodium azide treatment. GFP-filled
neurons were scored for neuronal health by an observer blind to condition, and were
considered degenerated if they displayed shrinking and/or dimming of the soma (see Figure
3B: the VC5 neuron in the D3 animal is considered degenerated). The same observer scored
neurodegeneration in each dataset. The percentage degeneration of VC4 and VC5 neurons
was measured out of the total number of neurons scored (>60 neurons). The percentage that
succumbed to APP-induced degeneration was compared for different groups (strain, drug
condition) using planned Fisher’s exact tests (Zar 1999).
Experimental designs for in vivo studies
All animals were single-housed at the start of drug administration and kept under a reverse
light-dark cycle with lights off at 8:30 AM and on at 8:30 PM in a temperature- and
humidity-controlled environment and given food and water ad libitum. All experiments were
in accordance with protocols approved by the Stanford University Administrative Panel for
Laboratory Animal Care and conformed to the U.S. National Institutes of Health Guide for
the Care and Use of Laboratory Animals. For pharmacokinetic (PK) study, male C57Bl/6J
mice at 2–3 month age were used (Jackson Laboratory). For efficacy studies, male Thy1-
hAPPLond/Swe+ (APPLond/Swe+) and their age-matched (4.5 to 6.7 month-old) wild-type
(WT) littermates were used as a mouse model of AD (Rockenstein et al. 2001). This
transgenic line was maintained by crossing heterozygous Thy1-hAPPLond/Swe+ mice with
C57BL/6J breeders. The genotype of all mice was determined by PCR using tail-tip DNA.
For the PK study, a total of 9 C57Bl/6J mice (n=3 per route) were used. For the efficacy
studies, two separate cohorts of APPLond/Swe+ mice were used in two independent studies. In
study I, a total of 43 mice were used in 4 experimental groups (n=9–12 mice per group) to
Yi et al. Page 4
J Neurochem. Author manuscript; available in PMC 2017 February 16.
Author M
anuscriptA
uthor Manuscript
Author M
anuscriptA
uthor Manuscript
assess the chronic daily dosing effect of SAS-0132 at 10mg/kg. In study II, a total of 38
mice were used in 8 experimental groups (n=4–5 mice per group) to assess the dose-
response effects of chronic daily dosing of SAS-0132 at 3, 10, and 30mg/kg. Since the
maximum feasible number of mice to be tested during a testing day is 35–45, we had to
reduce the group size to 4–5 animals per group in the dose response study. For details, see
Supplemental table 1.
PK study
Mice were dosed with 10 mg/kg of SAS-0132 intravenously, subcutaneously, or via oral
gavage. Retro-orbital blood samples were collected before drug administration, and 5 min,
30 min, 1 h after drug administration. Three hours post-dose, mice were sacrificed, and
blood samples were collected by cardiac puncture. Subsequently, brains were collected after
perfusion with PBS. Plasma was immediately separated by centrifugation and stored at
−80°C until analysis. The brain tissue samples were homogenized using distilled water and
the homogenates were stored at −80°C until analysis. The concentration of SAS-0132 was
then determined using LC/MS. The bioavailability was calculated as the ratio of
subcutaneous or oral to intravenous area under the curve calculated up to the last measured
time point (AUC(0–3h)).
Drug Treatment and Behavioral Testing
SAS-0132 (purity > 95%; HPLC) was synthesized as previously described (Sahn et al.
2016). For the in vivo studies, solutions of SAS-0132 were freshly prepared daily before
administration as described in the Appendix supplemental information. In the in vivo efficacy studies, APPLond/Swe+ and WT littermates were pseudo-randomly assigned to
vehicle or drug groups based on the body weight and the locomotor activity determined in
the pre-drug administration activity chamber test so that experimental groups were balanced
for the body weight and locomotor activity. In the chronic daily dosing study, APPLond/Swe+
and WT mice were administered vehicle or SAS-0132 at a dose of 10 mg/kg once a day for
64 days. In the chronic daily dosing dose-response study, APPLond/Swe+ and WT mice were
administered vehicle or SAS-0132 at doses of 3, 10, or 30 mg/kg daily for 60 days. Our
previous studies have shown 4 weeks of treatment is sufficient to detect chronic effects of
drugs with a diverse range of mechanisms in this mouse model (Nguyen et al. 2014b). Thus,
all animals from the in vivo study cohorts were evaluated in a battery of cognitive and
behavioral tests in the following order during the animal’s active cycle: Activity chamber,
Social discrimination, Morris Water Maze (MWM, only in the dose-response study), and Y-
maze tests as previously described during the last 4–9 weeks of drug administration
(Coutellier et al. 2014, Faizi et al. 2012). See the Appendix supplemental information for
behavioral testing procedure. All behavior tests were performed blindly by investigators
being blind to the treatment groups and genotypes. More specifically, the animals were
housed singly and were coded with animal IDs corresponding to the earmarks. All data
collections were done using these codes and the data were processed and analyzed blindly
based on group codes independent of treatment and genotype. The dosing was performed by
dosing personnel who were not collecting experimental data from the animals. All results
were re-analyzed and confirmed by a second investigator who was unware of the
experimental groups. In both efficacy studies, mice were tested in two cohorts divided
Yi et al. Page 5
J Neurochem. Author manuscript; available in PMC 2017 February 16.
Author M
anuscriptA
uthor Manuscript
Author M
anuscriptA
uthor Manuscript
between morning and afternoon sessions with treatment groups balanced between sessions.
SAS-0132 was subcutaneously administered in the late afternoon except on those days
behavioral testing occurred in which mice were dosed after testing to minimize acute effects
of the drug administration on behavior. No exclusion was made for the behavior test
analyses with the exception of MWM. In MWM, a total of 6 mice from WT-vehicle,
APPLond/Swe+-3 mg/kg, APPLond/Swe+-10 mg/kg, and APPLond/Swe+-30 mg/kg groups were
excluded based on extensive floating and swimming inability.
Tissue collection and biochemical analysis
After the behavioral testing was completed, mice were sacrificed and perfused with PBS,
and the brains were collected. The brains were sagittally bisected; half of the brain was
frozen and stored at −80°C until use; the other half was placed overnight in 4% formalin and
transferred and kept at 4°C in 30% sucrose until processed. To determine if chronic
administration of SAS-0132 leads to any toxic effects, blood and organs were collected and
used for blood chemistry and histopathology studies. To determine the effects of SAS-0132
on AD-related pathology, quantitative RT-PCR (qRT-PCR), ELISA and
immunohistochemical analyses were performed following the previously reported methods
(Schmittgen & Livak 2008, Maier et al. 2008, Johnson-Wood et al. 1997). Details are
described in Appendix supplemental information.
Statistics
In order to obtain 80% power in our in vivo efficacy studies, we conducted a power-analysis
using our historical data to detect a statistically significant difference of 20% in one single
behavioral task and determined to use 9–12 mice per group when feasible.
Statistical analyses were performed with the IBM SPSS Statistical Package 22.0 and Prism
5.0 (GraphPad Software). The calcium assay and qRT-PCR data were analyzed by one-way
analyses of variance (ANOVA), followed by Dunnett’s test for post-hoc analysis. C. elegans neurodegeneration data analyses were performed with Fisher's exact tests. Behavioral and
biochemical data analyses were performed with either t-test (Y-maze and social
discrimination tests, immunohistochemistry data), repeated measures of ANOVA, or
ANOVA followed by Fisher’s LSD or Dunnett’s post-hoc analyses (MWM). In all cases,
outliers were excluded according to Grubbs’ test and p < 0.05 was considered to be
significant.
RESULTS
Biological properties of SAS-0132 and related Sig2R/PGRMC1 binding ligands in vitro
Sigma receptor binding affinities of some norbenzomorphans—SAS-0132
(Figure 1) is a member of a novel family of Sig2R binding ligands with a 9-fold preference
for Sig2R (Ki 90 nM) over Sig1R (Ki 841 nM) (Sahn et al. 2016). It also exhibits low off-
target affinity (Ki > ~0.5 to 10 µM) for most CNS-relevant targets, including opioid,
adrenergic, nACR, mAChR, and NMDA receptors, as well as the neurotransmitter
transporters and ion channels (Supplemental table 2). Two structurally related compounds,
DKR-1005 and DKR-1051 also show similar degree of selectivity for Sig2R over Sig1R,
Yi et al. Page 6
J Neurochem. Author manuscript; available in PMC 2017 February 16.
Author M
anuscriptA
uthor Manuscript
Author M
anuscriptA
uthor Manuscript
whereas another structural analog JVW-1009 is approximately equipotent for both SigR
subtypes (Figure 1).
Effects of Sig2R binding ligands on intracellular calcium—Sig2R agonists have
been reported to modulate intracellular Ca2+ levels (Vilner & Bowen 2000, Cassano et al. 2009). Thus, we tested the effects of DKR-1051 and SAS-0132 on intracellular Ca2+ levels
in human SK-N-SH neuroblastoma cells. DKR-1051 induces concentration-dependent
increases in intracellular Ca2+ concentration, suggesting that it has agonist properties (Figure
2A). SAS-0132 fails to produce a significant calcium response at concentrations up to 30
µM, but induces significant increases in intracellular Ca2+ at 100 µM (Figure 2B). At 100
µM, the effects of SAS-0132 on intracellular Ca2+ are weaker than the effects of DKR-1051.
As SAS-0132 has no effect on intracellular Ca2+ at concentrations up to 30 µM, we
examined whether these lower concentrations of SAS-0132 can antagonize the calcium
response induced by DKR-1051. To evaluate the antagonistic effects of SAS-0132,
SAS-0132 was applied prior to adding the putative Sig2R/PGRMC1 agonist DKR-1051 in
order to allow SAS-0132 to first interact with the receptor in the absence of DKR-1051. To
maximize the signal window to detect antagonistic effects, we also used the high
concentration of DKR-1051 (i.e., 100 µM), which produces a robust calcium response.
Notably, SAS-0132 significantly attenuated the DKR-0151-induced calcium response at the
lower concentrations which are not associated with significant calcium response (Figure
2C).
Sig2R/PGRMC1 antagonists are neuroprotective—Given that Sig2R/PGRMC1
appears to be involved in neuroprotection (Izzo et al. 2014b, Cahill 2007, Rohe et al. 2009),
we queried whether any of our compounds might improve the survival of neurons in a C. elegans model of neurodegeneration. This novel transgenic model has a single copy insertion
of human amyloid precursor protein 695 (SC_APP) under a pan-neuronal promoter in
addition to the endogenous worm APP-like protein, apl-1. VC class neurons along the
ventral cord are genetically manipulated to express a fluorescent label, so neurodegeneration
in the transparent bodies of live worms can be easily monitored (Figures 3A,B).
Degeneration in two cholinergic neurons, VC4 and VC5, is characterized by shrinking
somas visible in both fluorescence and phase-contrast images, and dimming GFP-labeling
(Figure 3B). The presence of SC_APP in this worm model increases the rate of degeneration
(% degeneration out of the total number of neurons scored) of these cholinergic neurons in
an age-dependent manner (Figure 3C). Notably, neuronal degradation in the SC_APP strain
was significantly diminished by two different loss-of-function alleles of vem-1, a C. elegans ortholog of PGRMC1 (Figure 3D; Fisher’s exact test (n = 194–230), SC_APP strain vs. each
SC_APP; vem-1(null) strain, p < 0.01 and 0.001, respectively). Neurodegeneration was
similarly diminished by pharmacological modulation of VEM-1 with Sig2R/PGRMC1
binding ligands (Figure 3E). A 5-day treatment of SC_APP worms with SAS-0132 and the
structural analog JVW-1009 (200 µM) decreased neurodegeneration on day 5 of adulthood
when compared to the vehicle treated group (Figure 3E; Fisher’s exact test (n = 116–378),
SAS-0132 or JVW-1009 vs. vehicle, p < 0.01). In contrast, neurodegeneration was
exacerbated in SC_APP worms treated with DKR-1005 relative to the control group (Figure
3E; Fisher’s exact test (n = 110–378), DKR-1005 vs. vehicle, p < 0.01). Importantly,
Yi et al. Page 7
J Neurochem. Author manuscript; available in PMC 2017 February 16.
Author M
anuscriptA
uthor Manuscript
Author M
anuscriptA
uthor Manuscript
JVW-1009 and SAS-0132 both reduced neurodegeneration in SC_APP C. elegans but
provided no further neuroprotection in animals with vem-1 (PGRMC1) expression knocked-
down by RNAi (Figure 3F; Fisher’s exact test (n = 110–142), sham vs. RNAi, p < 0.001;
RNAi vs. JVW-1009 or double treatment, n.s., Figure 3G; Fisher’s exact test (n = 130–138),
sham vs. RNAi, p<0.01; RNAi vs. SAS-0132 or double treatment, n.s.). This suggests that
neuroprotection occurs via inhibition of a PGRMC1-mediated pathway. As the effects of the
Sig2R/PGRMC1 null mutations are redundant to the effects of JVW-1009 and SAS-0132
and contrary to the effects of DKR-1051, we have classified JVW-1009 and SAS-0132 as
Sig2R/PGRMC1 antagonists and DKR-1005 as a Sig2R/PGRMC1 agonist.
SAS-0132 is bioavailable and crosses the blood-brain barrier
The finding that the Sig2R antagonists SAS-0132 and JVW-1009 have neuroprotective
effects suggested that they might mitigate neuronal damage in neurodegenerative diseases
such as AD. Toward evaluating this intriguing possibility, we determined the PK properties
of SAS-0132. Detectable levels of SAS-0132 were measured in plasma up to 3 h post-
administration of 10 mg/kg through intravenous, subcutaneous, and oral administration
(Figure 4A). The bioavailability of SAS-0132 was 45% and 7% after subcutaneous and oral
administration, respectively (Figure 4B). Consistent with its favorable ClogD (3.5; pH=7.4),
SAS-0132 readily crosses the blood-brain-barrier and achieves a brain concentration of 3.8
µM (subcutaneous administration) and brain/plasma ratio above 7 through all routes of
administration at 3 h post-administration (Figures 4C,D). The finding that only a trace (1.6
ng/g) of SAS-0132 could be detected in brain homogenates 24 h after a single injection of
SAS-0132 (10 mg/kg, subcutaneous administration) suggests that it does not accumulate in
the brain.
SAS-0132 improves cognitive performance in APPLond/Swe+ mice
Having confirmed the bioavailability and brain permeability of SAS-0132, we assessed
whether chronic treatment with SAS-0132 might alleviate the cognitive deficits associated
with AD in an animal model of the disease. We selected the APPLond/Swe+ transgenic mouse
model, which expresses human APP751 cDNA containing the London (V717I) and Swedish
(K670M/N671L) mutations under the regulatory control of the murine Thy1 gene
(Rockenstein et al. 2001, Rockenstein et al. 2007); these animals exhibit cognitive deficits in
several behavioral tests (Nguyen et al. 2014b, Faizi et al. 2012, Coutellier et al. 2014). Two
separate cohorts of mice were used to assess chronic daily dosing and chronic daily dosing
dose-response effects of SAS-0132. Importantly, all behavioral tests were conducted prior to
administration of the daily dose of SAS-0132 when SAS-0132 from the previous day’s
dosing is expected to be cleared from the brain.
In the chronic daily dosing study, daily dosing of APPLond/Swe+ mice and their WT
littermates with SAS-0132 (10 mg/kg) was initiated at 4.5 months of age and continued for
64 days. In the sociability test performed after 35 days of dosing, vehicle-treated WT
animals showed a normal sociability by showing preference for the cup containing a mouse
over the empty cup; this preference was not significantly altered by SAS-0132 treatment
(Figure 5A, t-test, mouse versus empty cup, * p < 0.05). In contrast, vehicle-treated
APPLond/Swe+ mice exhibited impaired sociability and showed no preference between the
Yi et al. Page 8
J Neurochem. Author manuscript; available in PMC 2017 February 16.
Author M
anuscriptA
uthor Manuscript
Author M
anuscriptA
uthor Manuscript
mouse and empty cup (Figure 5A, t-test, mouse vs. empty cup, n.s.). The SAS-0132 treated
APPLond/Swe+ mice showed a distinct preference for the cup containing a mouse over the
empty cup (Figure 5A, t-test, mouse vs. empty cup, * p < 0.05). In the Y-maze test
performed after 50 days of dosing, vehicle-treated APPLond/Swe+ mice were impaired as
assessed by low spontaneous alternation behavior in contrast to the WT mice (Figure 5B,
one-sample t-test vs. 50% theoretical mean, ** p < 0.01, *** p < 0.001). APPLond/Swe+ mice
treated with SAS-0132 showed an alternation level comparable to vehicle-treated WT mice
(Figure 5B, one-sample t-test vs. 50% theoretical mean, * p < 0.05). Total arm entries were
not different among the four groups (Figure 5B).
In the chronic daily dosing dose-response study, APPLond/Swe+ mice and their WT
littermates were aged to 6.7 months prior to initiating the administration of SAS-0132 at
doses of 3, 10, and 30 mg/kg for a total of 60 days. In a social discrimination task performed
after 30 days of dosing, all groups show normal sociality except for WT and APPLond/Swe+
mice treated with 10 mg/kg of SAS-0132 (Data not shown). We attribute this observation to
animal variations because the higher dose of 30 mg/kg did not impair sociability. The social
discrimination test was performed 1 day after the sociability test, and only APPLond/Swe+
mice treated with 3 mg/kg of SAS-0132 showed a significant preference for a novel mouse
over a familiar one (Figure 6A, t-test, familiar vs. novel). In the Y-maze test, which was
performed after 45 days of dosing, vehicle-treated APPLond/Swe+ mice showed a deficit in
spontaneous alternation behavior (Figure 6B, one-sample t-test vs. 50% theoretical mean,
n.s.), whereas those treated with 3 and 10 mg/kg of SAS-0132 showed normal spontaneous
alternation behavior (Figure 6B, one-sample t-test vs. 50% theoretical mean, n.s.).
Administration of 3 and 10 mg/kg of SAS-0132 to WT mice did not affect their
performance, but those dosed with 30 mg/kg showed impaired alternation behavior,
suggesting that high doses of SAS-0132 might have adverse effects on memory (Figure 6B,
one-sample t-test vs. 50% theoretical mean, n.s.). The number of total arm entries was not
different among groups (Figure 6B). The MWM test was initiated after 35 days of dosing.
During the hidden platform learning period, WT mice treated with 3 and 30 mg/kg of
SAS-0132 found the escape platform faster than the vehicle-treated WT mice (Figure 6C,
repeated measures of ANOVA, * p < 0.05, Dunnett’s post-hoc analysis, * p < 0.05). When
the platform was removed, vehicle-treated WT mice did not show target quadrant
preference, whereas WT mice treated with 3 mg/kg of SAS-0132 showed a clear preference
for the target quadrant (Figure 6C. t-test, target vs. non-target quadrant, * p < 0.01).
Administration of SAS-0132 had no effect on the cognitive functions of APPLond/Swe+
animals during the hidden platform learning phase (Figure 6D). After the spatial learning
phase, the reversal learning hidden platform trial was performed. On day 2 of this training,
WT mice treated with 10 and 30 mg/kg of SAS-0132 found the escape platform faster than
WT mice treated with vehicle (Figure 6E, one-way ANOVA, * p < 0.05, Fisher’s LSD, * p ≤
0.05). With the exception of the group treated with 3 mg/kg of SAS-0132, all WT groups
demonstrated recall and showed target quadrant preference during the reversal learning
probe trial (Figure 6E, paired t-test, target versus non-target quadrant, * p < 0.05, *** p <
0.001). There were no significant effects of SAS-0132 treatment in APPLond/Swe+ mice
during the reversal learning trials (Figure 6F). During the reversal learning probe trial,
vehicle-treated APPLond/Swe+ mice did not show a preference for the target quadrant over the
Yi et al. Page 9
J Neurochem. Author manuscript; available in PMC 2017 February 16.
Author M
anuscriptA
uthor Manuscript
Author M
anuscriptA
uthor Manuscript
non-target quadrants, whereas APPLond/Swe+ mice treated with 10 mg/kg of SAS-0132
showed target quadrant preference, indicating that SAS-0132 treatment reversed the reversal
training probe deficits in the APPLond/Swe+ group (Figure 6F, paired t-test, target vs. non-
target quadrant, * p < 0.05).
In both chronic daily dosing and chronic daily dosing dose-response studies, animals treated
with SAS-0132 remained healthy and exhibited no detectable abnormalities. Locomotor
activity measured in the activity chamber test after 24 days of treatment was not significantly
different between vehicle- and SAS-0132-treated mice, indicating that general locomotor
activity were not affected by SAS-0132 (data not shown). Comprehensive blood chemistry
and histopathology studies conducted using plasma and organs obtained from WT mice
treated with vehicle and SAS-0132 (10 mg/kg/d for 64 days) revealed no signs of SAS- 0132
induced toxicity (Supplemental tables 3–4).
Effects of SAS-0132 treatment upon Aβ pathology, synaptic loss, and neuroinflammation
Upon completion of the behavioral tests, we queried whether the cognitive-enhancing effects
of SAS-0132 might be attributable to its effects on AD-related pathological features. In
vehicle treated APPLond/Swe+ mice from the chronic daily dosing study (6.5 months old at
tissue collection), increased intracellular Aβ immunoreactivity was observed in the cortex,
hippocampus, and amygdala, relative to vehicle-treated WT group (Supplemental figure 1A,
*** p < 0.001 vs. WT groups, independent samples t-test). APPLond/Swe+ animals treated
with SAS-0132 displayed Aβ immunoreactivity similar to that seen in the vehicle-treated
APPLond/Swe+ groups, indicating that chronic treatment with SAS-0132 does not affect levels
of intracellular Aβ (Supplemental figure 1A). Similarly, ELISA analysis using brains of
these animals revealed no significant difference in soluble and insoluble Aβ40 and Aβ42
between vehicle- and SAS-0132-treated APPLond/Swe+ mice (Supplemental figure 1B,
independent samples t-test). Collectively, these data indicate that SAS-0132 does not affect
Aβ burden in the APPLond/Swe+ mouse model of AD.
Because Aβ is known to be toxic to synapses and to induce a neuroinflammatory response
(Shankar et al. 2007, Koffie et al. 2009, Meyer-Luehmann et al. 2008, Halle et al. 2008), we
determined whether SAS-0132 affects synaptic pathology and the neuroinflammatory
response. Quantifying the immunoreactivity of the pre-synaptic marker synaptophysin
revealed a significant reduction in synaptophysin levels in the CA3 region of APPLond/Swe+
mice compared to WT mice (chronic daily dosing study cohort, 6.5 months old at tissue
collection), but chronic treatment with SAS-0132 (10 mg/kg/d) did not alter the extent of
synapse loss (Supplemental figure 2). With respect to neuroinflammation, quantitative
immunohistochemistry with iba1 did not reveal any differences in microglia/monocyte-
derived macrophages in vehicle-treated APPLond/Swe+ mice relative to vehicle-treated WT
mice (chronic daily dosing study cohort, 6.5 months old at tissue collection).There were no
drug-related effects on immunoreactivity for iba1 in either WT or APPLond/Swe+ mice
(Supplemental figure 2). On the other hand, qRT-PCR analysis revealed that APPLond/Swe+
animals had elevated inflammatory markers TNFα, CD14, and IL1β at 8.75 months (dose-
response cohort), although elevation of the IL1β was not significant at 8.75 months (dose-
Yi et al. Page 10
J Neurochem. Author manuscript; available in PMC 2017 February 16.
Author M
anuscriptA
uthor Manuscript
Author M
anuscriptA
uthor Manuscript
response cohort) (Figure 7). Notably, treatment with SAS-0132 decreased the expression of
the inflammatory cytokine IL1β (Figure 7).
DISCUSSION
In this study, we report the identification of a novel norbenzomorphan class of Sig2R/
PGRMC1 ligands and their cellular and in vivo activity. The Sig2R/PGRMC1 ligands
reported here have Ki values in the low nanomolar range, which are comparable to the Ki
values of other known Sig2R/PGRMC1 ligands (Guo & Zhen 2015, Huang et al. 2014,
Vilner & Bowen 2000). The three ligands (i.e. SAS-0132, DKR-1005, and DKR-1051)
display selectivity for Sig2R/PGRMC1 over the Sig1R, with selectivity ratios greater than 9.
The discovery of this novel class of Sig2R/PGRMC1 ligands is of great importance, as these
norbenzomorphans have favorable pharmacokinetic attributes required for CNS indications.
In addition, they have compact molecular scaffolds and are amenable to structure-activity
relationship studies. Thus, norbenzomorphan analogs may be promising candidates for
further development into drug leads.
Regulation of intracellular Ca2+ is one important cellular process mediated by Sig2R/
PGRMC1, and structurally diverse Sig2R agonists are known to promote the release of
calcium from the endoplasmic reticulum and mitochondria (Cassano et al. 2009, Vilner &
Bowen 2000, Brent et al. 1996). We have shown that DKR-1051 produces concentration-
dependent increases in intracellular Ca2+ levels, suggesting that DKR-1051 has agonist
properties (Figure 2A). The other Sig2 binding ligand SAS-0132 failed to produce a
significant calcium response at up to 30 µM. At 100 µM, however, SAS-0132 increased
intracellular Ca2+ levels, but its effects on intracellular Ca2+ levels were weaker than the
effects of DKR-1051 (Figures 2A–2B). Interestingly, SAS-0132 attenuated the calcium
response induced by DKR-1051 at the lower concentrations that have no effect on
intracellular Ca2+ levels alone (Figure 2C). Collectively, this observation suggests that
SAS-0132 is an antagonist of Sig2R/PGRMC1 that has partial agonist activity. At the
molecular level, Sig2R/PGRMC1 could potentially modulate intracellular Ca2+ by indirectly
influencing the activity of ion-channels expressed in the endoplasmic reticulum,
mitochondria, and cell membrane (Vilner & Bowen 2000). As Sig2R/PGRMC1 is localized
in high density to subcellular fractions known to store calcium (Basile et al. 1992), another
possibility is that Sig2R/PGRMC1 directly gate the release of calcium. Further studies will
be needed to determine the exact mechanisms by which Sig2R agonists increase intracellular
calcium concentrations. Sig2R/PGRMC1-mediated calcium mobilization has important
clinical implications because intracellular Ca2+ plays a critical role in learning and memory,
and is strongly implicated in neuronal health (Bezprozvanny 2009). Perturbed Ca2+
homeostasis also appears to be involved in the dysfunction and death of neurons (Demuro et al. 2010, Mattson 1994), and its probable role in AD pathogenesis is supported by studies of
animal models of AD as well as of patients (Bezprozvanny & Mattson 2008, Zhang et al. 2015, Chakroborty et al. 2012). Because Ca2+ dyshomeostasis is a pathological feature of
AD and other neurodegenerative diseases (Berridge 2010), restoring Ca2+ homeostasis via
modulation of Sig2R/PGRMC1 may be a promising new approach to treat
neurodegenerative disorders.
Yi et al. Page 11
J Neurochem. Author manuscript; available in PMC 2017 February 16.
Author M
anuscriptA
uthor Manuscript
Author M
anuscriptA
uthor Manuscript
C. elegans is well-suited as a model organism for human diseases because it has clear
orthologs for two-thirds of all human genes (Hulme & Whitesides 2011, Consortium 1998,
Sonnhammer & Durbin 1997, Lai et al. 2000, Kuwabara & O'Neil 2001). Relevant to our
study, C. elegans expresses vem-1, an ortholog of PGRMC1, as well as other genes involved
in AD-related pathways (Link 2006, Simonsen et al. 2012, Safra et al. 2013, Haynes & Ron
2010, Runko & Kaprielian 2004). Our results demonstrate that single copy insertion of the
human APP gene into the C. elegans genome leads to age-dependent degeneration of
cholinergic neurons. While previous studies have not examined age-dependent
neurodegeneration, multi-copy overexpression of the C. elegans ortholog of APP (apl-1) or
human APP has been shown to cause behavioral dysfunction and partial lethality in C. elegans (Hornsten et al. 2007, Ewald et al. 2012). Importantly, the neurodegeneration we
observed in transgenic APP worms was diminished by genetic manipulation of PGRMC1 or
by pharmacological inhibition with SAS-0132 and JVW-1009. Conversely,
neurodegeneration was exacerbated by treatment with the agonist DKR-1005 (Figure 3).
These findings provide in vivo genetic evidence that PGRMC1 is critically involved in APP-
mediated neurodegeneration, and the Sig2R antagonists SAS-0132 and JVW-1009 exert
neuroprotection via a PGRMC1-related pathway.
In chronic daily dosing and chronic daily dosing dose-response studies, significant cognitive
enhancing effects of SAS-0132 were observed in both transgenic and WT animals. In the
chronic daily dosing study, SAS-0132 rescued AD-related sociability deficits and spatial
memory deficits (Y-maze-test). In the chronic daily dosing dose-response study, SAS-0132
rescued deficits in the social discrimination test (3 mg/kg) as well as deficits in spatial
memory in the Y-maze test (3 mg/kg and 10 mg/kg). SAS-0132 also led to improvements in
spatial and long-term memory in both WT (3, 10 and 30 mg/kg) and APPLond/Swe+ mice (10
mg/kg) in the MWM test. Although the cognitive enhancing effects of SAS-0132 shown in
the chronic daily dosing dose-response study should be interpreted cautiously due to the
small sample size, it is noteworthy that the effects of SAS-0132 were sufficiently large to be
detected despite the low statistical power. Importantly, cognitive performance of the animals
was evaluated prior to administration of the daily dose of SAS-0132. Because SAS-0132 is
largely cleared from the brain within 24 hours, the observed improvements in cognitive
performance likely arose from sustained modulation of Sig2R/PGRMC1 rather than from an
acute effect from treatment with SAS-0132.
There are several mechanisms that might explain the cognition-enhancing effects of
SAS-0132. First, SAS-0132 could produce pro-cognitive effects by being neuroprotective
against APP-mediated neuronal toxicity. For example, the Sig2R binding ligands CT01344
and CT01346 were found to block binding of Aβ oligomers to Sig2R/PGRMC1 and restore
AD-related behavioral deficits in the APPLond/Swe+ mouse model of AD (Izzo et al. 2014a).
Second, by regulating intracellular calcium levels, SAS-0132 treatment may counteract Aβ related dysregulation of calcium homeostasis. For example, application of Aβ oligomers to
cultured neurons induces an unregulated flux of Ca2+ through the plasma membrane via
various mechanisms that include activating endogenous receptors coupled to Ca2+ influx,
disrupting membrane lipid integrity, and forming Ca2+-permeable channels (Arispe et al. 1993, Rovira et al. 2002, Kayed et al. 2004, Demuro et al. 2010). Dysregulated Ca2+
homeostasis can trigger detrimental processes such as apoptosis and free radical formation,
Yi et al. Page 12
J Neurochem. Author manuscript; available in PMC 2017 February 16.
Author M
anuscriptA
uthor Manuscript
Author M
anuscriptA
uthor Manuscript
and these adverse events can eventually lead to cognitive deficits. Thus, with its ability to
modulate intracellular Ca2+ concentration, SAS-0132 may lead to cognitive enhancing
effects. Last, the benefits of SAS-0132 might not be exclusively related to its effects on APP
related pathways, but result from more generalized mechanisms that are not specific to APP.
For example, in our dose-response study, we discovered that chronic treatment of WT mice
with SAS-0132 improved spatial and long-term memory in the MWM test. Although further
studies are required to confirm this finding, these cognitive enhancing effects of SAS-0132
in healthy animals certainly warrant further study.
In contrast to its significant effect on cognition, SAS-0132 had no discernible effects upon
several markers of AD pathology, including Aβ burden and synaptic loss. As
neuroinflammation is one of the main pathological features of AD, we also sought to
determine the effects of SAS-0132 on neuroinflammation. In the chronic daily dosing study,
we were unable to evaluate the effects of SAS-0132 on AD-related neuroinflammation, as
APPLond/Swe+ mice showed little evidence of neuroinflammation. Although this finding is
interesting as high levels of Aβ and behavioral deficits associated with AD are present in
this APPLond/Swe+ mice at this age, it is in line with a previous study that reported the lack of
signs of neuroinflammation in this mouse model at 8 months of age (Lull et al. 2011).
Multiple lines of transgenic models of AD have been shown to develop AD-related
neuropathology in an age-dependent manner (Abbas et al. 2002, Sly et al. 2001, Oakley et al. 2006, Rockenstein et al. 2001). Thus, it is possible that the APPLond/Swe+ mice model
may show evidence of neuroinflammation at older age. Indeed, we observed significant
increases in expression of neuro-inflammatory genes in APPLond/Swe+ mice compared to WT
mice in the chronic daily dosing dose-response study (8.7 months of age at tissue
collection). Chronic treatment with SAS-0132 was shown to decrease AD-related
neuroinflammatory responses as measured by reduced brain levels of the inflammatory
cytokine IL1β. Because chronic inflammation in response to neuronal damage is thought to
accelerate and potentially underlie disease progression in AD (Heneka et al. 2015), the anti-
inflammatory effects of SAS-0132 might be partly responsible for its cognitive enhancing
effects.
In this study, we report that pharmacological and genetic inhibition of Sig2R is
neuroprotective, cognitive enhancing, and anti-inflammatory in experimental models of AD
and excessive amyloidosis. Regulation of intracellular calcium concentration by Sig2R
modulation could be responsible for these beneficial effects. Further mechanistic studies will
be needed to investigate the role of the Sig2R/PGRMC1 in modulation of
neuroinflammation and cellular signaling, leading to neuroprotection and modulation of
intracellular calcium homeostasis. The fact that the Sig2R/PGRMC1 antagonist SAS-0132
has significant benefits when it is chronically administered to symptomatic animals inspires
the intriguing question of whether treatment of presymptomatic animals could prevent the
development of AD and/or cognitive deficits. Our findings clearly demonstrate the
significant potential of modulating pathways mediated by Sig2R/PGRMC1 as a novel
mechanism to treat AD. This hypothesis is supported by recent work conducted by Izzo and
coworkers, who have shown that CT01344 and CT01346: (1) block binding of Aβ oligomers
to Sig2R/PGRMC1 on neurons (Izzo et al. 2014a, Izzo et al. 2014b); (2) prevent and reverse
the effects of Aβ oligomers on membrane trafficking and synapse loss in neuronal culture
Yi et al. Page 13
J Neurochem. Author manuscript; available in PMC 2017 February 16.
Author M
anuscriptA
uthor Manuscript
Author M
anuscriptA
uthor Manuscript
(Izzo et al. 2014a); and (3) reverse cognitive deficits in a mouse model of AD (Izzo et al.
2014a). These collective discoveries suggest that modulating pathways mediated by Sig2R/
PGRMC1 is meritorious as a new approach to study neurodegenerative conditions and, if
shown to be safe and well tolerated, should be further evaluated.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
Acknowledgments and dedication
Receptor binding profiles was performed by the National Institute of Mental Health's Psychoactive Drug Screening Program (NIMH PDSP). We thank the director of NIMH PDSP, Bryan L. Roth MD, PhD, at the University of North Carolina at Chapel Hill and Project Officer Jamie Driscoll at NIMH, Bethesda MD, USA. For the C. elegans study, some strains were provided by CGC, which is supported by the NIH Office of Research Infrastructure Programs (P40 OD010440). This manuscript is dedicated to Dr. Steven Alan Sahn: a brilliant physician, a dedicated and passionate coach, and a loving and devoted father.
Funding
This study was supported by National Institutes of Health (GM 24539, 1R01AG041135, NS069375), Robert A. Welch Foundation (F-0652), Alzheimer’s Association, and Lumind Research Foundation. We are also grateful to Dr. Richard Pederson (Materia, Inc.) for catalyst support.
Abbreviations used
AD Alzheimer’s disease
Sig1R sigma 1 receptor
Sig2R sigma 2 receptor
PGRMC1 progesterone receptor membrane component-1
References
http://www.proteinatlas.org/ENSG00000101856-PGRMC1/tissue
Abate C, Niso M, Infantino V, Menga A, Berardi F. Elements in support of the 'non-identity' of the PGRMC1 protein with the sigma2 receptor. Eur J Pharmacol. 2015; 758:16–23. [PubMed: 25843410]
Abbas N, Bednar I, Mix E, et al. Up-regulation of the inflammatory cytokines IFN-gamma and IL-12 and down-regulation of IL-4 in cerebral cortex regions of APP(SWE) transgenic mice. J Neuroimmunol. 2002; 126:50–57. [PubMed: 12020956]
Arispe N, Rojas E, Pollard HB. Alzheimer disease amyloid beta protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminum. Proc Natl Acad Sci U S A. 1993; 90:567–571. [PubMed: 8380642]
Basile AS, Paul IA, de Costa B. Differential effects of cytochrome P-450 induction on ligand binding to sigma receptors. Eur J Pharmacol. 1992; 227:95–98. [PubMed: 1426026]
Behensky AA, Yasny IE, Shuster AM, Seredenin SB, Petrov AV, Cuevas J. Stimulation of sigma receptors with afobazole blocks activation of microglia and reduces toxicity caused by amyloid-beta25–35. J Pharmacol Exp Ther. 2013; 347:458–467. [PubMed: 24006337]
Berridge MJ. Calcium hypothesis of Alzheimer's disease. Pflugers Arch. 2010; 459:441–449. [PubMed: 19795132]
Yi et al. Page 14
J Neurochem. Author manuscript; available in PMC 2017 February 16.
Author M
anuscriptA
uthor Manuscript
Author M
anuscriptA
uthor Manuscript
Besnard J, Ruda GF, Setola V, et al. Automated design of ligands to polypharmacological profiles. Nature. 2012; 492:215–220. [PubMed: 23235874]
Bezprozvanny I. Calcium signaling and neurodegenerative diseases. Trends Mol Med. 2009; 15:89–100. [PubMed: 19230774]
Bezprozvanny I, Mattson MP. Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease. Trends Neurosci. 2008; 31:454–463. [PubMed: 18675468]
Bowen WD. Sigma receptors: recent advances and new clinical potentials. Pharm Acta Helv. 2000; 74:211–218. [PubMed: 10812960]
Brenner S. The genetics of Caenorhabditis elegans. Genetics. 1974; 77:71–94. [PubMed: 4366476]
Brent PJ, Pang G, Little G, Dosen PJ, Van Helden DF. The sigma receptor ligand, reduced haloperidol, induces apoptosis and increases intracellularfree calcium levels [Ca2+]i in colon and mammary adenocarcinoma cells. Biochem Biophys Res Commun. 1996; 219:219–226. [PubMed: 8619811]
Cahill MA. Progesterone receptor membrane component 1: an integrative review. J Steroid Biochem Mol Biol. 2007; 105:16–36. [PubMed: 17583495]
Cassano G, Gasparre G, Niso M, Contino M, Scalera V, Colabufo NA. F281, synthetic agonist of the sigma-2 receptor, induces Ca2+ efflux from the endoplasmic reticulum and mitochondria in SK-N-SH cells. Cell Calcium. 2009; 45:340–345. [PubMed: 19187959]
Chakroborty S, Kim J, Schneider C, Jacobson C, Molgo J, Stutzmann GE. Early presynaptic and postsynaptic calcium signaling abnormalities mask underlying synaptic depression in presymptomatic Alzheimer's disease mice. J Neurosci. 2012; 32:8341–8353. [PubMed: 22699914]
Chu UB, Mavlyutov TA, Chu ML, Yang H, Schulman A, Mesangeau C, McCurdy CR, Guo LW, Ruoho AE. The Sigma-2 Receptor and Progesterone Receptor Membrane Component 1 are Different Binding Sites Derived From Independent Genes. EBioMedicine. 2015; 2:1806–1813. [PubMed: 26870805]
Citron M. Alzheimer's disease: strategies for disease modification. Nat Rev Drug Discov. 2010; 9:387–398. [PubMed: 20431570]
Consortium, C. e. S. Genome sequence of the nematode C. elegans: a platform for investigating biology. Science. 1998; 282:2012–2018. [PubMed: 9851916]
Coutellier L, Ardestani PM, Shamloo M. beta1-adrenergic receptor activation enhances memory in Alzheimer's disease model. Ann Clin Transl Neurol. 2014; 1:348–360. [PubMed: 24883337]
Cummings JL, Morstorf T, Zhong K. Alzheimer's disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res Ther. 2014; 6:37. [PubMed: 25024750]
Demuro A, Parker I, Stutzmann GE. Calcium signaling and amyloid toxicity in Alzheimer disease. J Biol Chem. 2010; 285:12463–12468. [PubMed: 20212036]
Ewald CY, Cheng R, Tolen L, Shah V, Gillani A, Nasrin A, Li C. Pan-neuronal expression of APL-1, an APP-related protein, disrupts olfactory, gustatory, and touch plasticity in Caenorhabditis elegans. J Neurosci. 2012; 32:10156–10169. [PubMed: 22836251]
Faizi M, Bader PL, Saw N, Nguyen TV, Beraki S, Wyss-Coray T, Longo FM, Shamloo M. Thy1-hAPP(Lond/Swe+) mouse model of Alzheimer's disease displays broad behavioral deficits in sensorimotor, cognitive and social function. Brain Behav. 2012; 2:142–154. [PubMed: 22574282]
French L, Pavlidis P. Relationships between gene expression and brain wiring in the adult rodent brain. PLoS Comput Biol. 2011; 7:e1001049. [PubMed: 21253556]
Frokjaer-Jensen C, Davis MW, Hopkins CE, Newman BJ, Thummel JM, Olesen SP, Grunnet M, Jorgensen EM. Single-copy insertion of transgenes in Caenorhabditis elegans. Nat Genet. 2008; 40:1375–1383. [PubMed: 18953339]
Guo L, Zhen X. Sigma-2 receptor ligands: neurobiological effects. Curr Med Chem. 2015; 22:989–1003. [PubMed: 25620095]
Halle A, Hornung V, Petzold GC, et al. The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol. 2008; 9:857–865. [PubMed: 18604209]
Hashimoto K. Sigma-1 receptor chaperone and brain-derived neurotrophic factor: emerging links between cardiovascular disease and depression. Prog Neurobiol. 2013; 100:15–29. [PubMed: 23044468]
Yi et al. Page 15
J Neurochem. Author manuscript; available in PMC 2017 February 16.
Author M
anuscriptA
uthor Manuscript
Author M
anuscriptA
uthor Manuscript
Haynes CM, Ron D. The mitochondrial UPR - protecting organelle protein homeostasis. J Cell Sci. 2010; 123:3849–3855. [PubMed: 21048161]
Heneka MT, Carson MJ, El Khoury J, et al. Neuroinflammation in Alzheimer's disease. Lancet Neurol. 2015; 14:388–405. [PubMed: 25792098]
Hornsten A, Lieberthal J, Fadia S, et al. APL-1, a Caenorhabditis elegans protein related to the human beta-amyloid precursor protein, is essential for viability. Proc Natl Acad Sci U S A. 2007; 104:1971–1976. [PubMed: 17267616]
Huang Y, Mucke L. Alzheimer mechanisms and therapeutic strategies. Cell. 2012; 148:1204–1222. [PubMed: 22424230]
Huang YS, Lu HL, Zhang LJ, Wu Z. Sigma-2 receptor ligands and their perspectives in cancer diagnosis and therapy. Med Res Rev. 2014; 34:532–566. [PubMed: 23922215]
Hulme SE, Whitesides GM. Chemistry and the worm: Caenorhabditis elegans as a platform for integrating chemical and biological research. Angew Chem Int Ed Engl. 2011; 50:4774–4807. [PubMed: 21500322]
Izzo NJ, Staniszewski A, To L, et al. Alzheimer's therapeutics targeting amyloid beta 1–42 oligomers I: Abeta 42 oligomer binding to specific neuronal receptors is displaced by drug candidates that improve cognitive deficits. PLoS One. 2014a; 9:e111898. [PubMed: 25390368]
Izzo NJ, Xu J, Zeng C, et al. Alzheimer's therapeutics targeting amyloid beta 1–42 oligomers II: Sigma-2/PGRMC1 receptors mediate Abeta 42 oligomer binding and synaptotoxicity. PLoS One. 2014b; 9:e111899. [PubMed: 25390692]
James BD, Leurgans SE, Hebert LE, Scherr PA, Yaffe K, Bennett DA. Contribution of Alzheimer disease to mortality in the United States. Neurology. 2014; 82:1045–1050. [PubMed: 24598707]
Johnson-Wood K, Lee M, Motter R, et al. Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease. Proc Natl Acad Sci U S A. 1997; 94:1550–1555. [PubMed: 9037091]
Kabe Y, Nakane T, Koike I, et al. Haem-dependent dimerization of PGRMC1/Sigma-2 receptor facilitates cancer proliferation and chemoresistance. Nat Commun. 2016; 7:11030. [PubMed: 26988023]
Kayed R, Sokolov Y, Edmonds B, McIntire TM, Milton SC, Hall JE, Glabe CG. Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. J Biol Chem. 2004; 279:46363–46366. [PubMed: 15385542]
Koffie RM, Meyer-Luehmann M, Hashimoto T, et al. Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc Natl Acad Sci U S A. 2009; 106:4012–4017. [PubMed: 19228947]
Kuwabara PE, O'Neil N. The use of functional genomics in C. elegans for studying human development and disease. J Inherit Metab Dis. 2001; 24:127–138. [PubMed: 11405335]
Lai CH, Chou CY, Ch'ang LY, Liu CS, Lin W. Identification of novel human genes evolutionarily conserved in Caenorhabditis elegans by comparative proteomics. Genome Res. 2000; 10:703–713. [PubMed: 10810093]
Link CD. C. elegans models of age-associated neurodegenerative diseases: lessons from transgenic worm models of Alzheimer's disease. Exp Gerontol. 2006; 41:1007–1013. [PubMed: 16930903]
Liu L, Wang J, Zhao L, Nilsen J, McClure K, Wong K, Brinton RD. Progesterone increases rat neural progenitor cell cycle gene expression and proliferation via extracellularly regulated kinase and progesterone receptor membrane components 1 and 2. Endocrinology. 2009; 150:3186–3196. [PubMed: 19359388]
Lull ME, Levesque S, Surace MJ, Block ML. Chronic apocynin treatment attenuates beta amyloid plaque size and microglial number in hAPP(751)(SL) mice. PLoS One. 2011; 6:e20153. [PubMed: 21655287]
Mach RH, Zeng C, Hawkins WG. The sigma2 receptor: a novel protein for the imaging and treatment of cancer. J Med Chem. 2013; 56:7137–7160. [PubMed: 23734634]
Maier M, Peng Y, Jiang L, Seabrook TJ, Carroll MC, Lemere CA. Complement C3 deficiency leads to accelerated amyloid beta plaque deposition and neurodegeneration and modulation of the microglia/macrophage phenotype in amyloid precursor protein transgenic mice. J Neurosci. 2008; 28:6333–6341. [PubMed: 18562603]
Yi et al. Page 16
J Neurochem. Author manuscript; available in PMC 2017 February 16.
Author M
anuscriptA
uthor Manuscript
Author M
anuscriptA
uthor Manuscript
Martin SF. Strategies for the synthesis of alkaloids and novel nitrogen heterocycles. Adv. Heterocyclic Chem. 2013
Matsumoto, RR., Bowen, WD., Su, T-P. Sigma receptors : chemistry, cell biology and clinical implications. New York: Springer; 2007.
Mattson MP. Calcium and neuronal injury in Alzheimer's disease. Contributions of beta-amyloid precursor protein mismetabolism, free radicals, and metabolic compromise. Ann N Y Acad Sci. 1994; 747:50–76. [PubMed: 7847692]
Mattson MP. Pathways towards and away from Alzheimer's disease. Nature. 2004; 430:631–639. [PubMed: 15295589]
Meyer-Luehmann M, Spires-Jones TL, Prada C, et al. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature. 2008; 451:720–724. [PubMed: 18256671]
Nguyen L, Kaushal N, Robson MJ, Matsumoto RR. Sigma receptors as potential therapeutic targets for neuroprotection. Eur J Pharmacol. 2014a; 743:42–47. [PubMed: 25261035]
Nguyen TV, Shen L, Vander Griend L, et al. Small molecule p75NTR ligands reduce pathological phosphorylation and misfolding of tau, inflammatory changes, cholinergic degeneration, and cognitive deficits in AbetaPP(L/S) transgenic mice. J Alzheimers Dis. 2014b; 42:459–483. [PubMed: 24898660]
Oakley H, Cole SL, Logan S, et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J Neurosci. 2006; 26:10129–10140. [PubMed: 17021169]
Qin Y, Chen Z, Han X, Wu H, Yu Y, Wu J, Liu S, Hou Y. Progesterone attenuates Abeta(25–35)-induced neuronal toxicity via JNK inactivation and progesterone receptor membrane component 1-dependent inhibition of mitochondrial apoptotic pathway. J Steroid Biochem Mol Biol. 2015; 154:302–311. [PubMed: 25576906]
Reitz C, Mayeux R. Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem Pharmacol. 2014; 88:640–651. [PubMed: 24398425]
Rockenstein E, Mallory M, Mante M, Sisk A, Masliaha E. Early formation of mature amyloid-beta protein deposits in a mutant APP transgenic model depends on levels of Abeta(1–42). J Neurosci Res. 2001; 66:573–582. [PubMed: 11746377]
Rockenstein E, Torrance M, Adame A, Mante M, Bar-on P, Rose JB, Crews L, Masliah E. Neuroprotective effects of regulators of the glycogen synthase kinase-3beta signaling pathway in a transgenic model of Alzheimer's disease are associated with reduced amyloid precursor protein phosphorylation. J Neurosci. 2007; 27:1981–1991. [PubMed: 17314294]
Rohe HJ, Ahmed IS, Twist KE, Craven RJ. PGRMC1 (progesterone receptor membrane component 1): a targetable protein with multiple functions in steroid signaling, P450 activation and drug binding. Pharmacol Ther. 2009; 121:14–19. [PubMed: 18992768]
Rovira C, Arbez N, Mariani J. Abeta(25–35) and Abeta(1–40) act on different calcium channels in CA1 hippocampal neurons. Biochem Biophys Res Commun. 2002; 296:1317–1321. [PubMed: 12207918]
Runko E, Kaprielian Z. Caenorhabditis elegans VEM-1, a novel membrane protein, regulates the guidance of ventral nerve cord-associated axons. J Neurosci. 2004; 24:9015–9026. [PubMed: 15483120]
Safra M, Ben-Hamo S, Kenyon C, Henis-Korenblit S. The ire-1 ER stress-response pathway is required for normal secretory-protein metabolism in C. elegans. J Cell Sci. 2013; 126:4136–4146. [PubMed: 23843615]
Sahn JJ, Granger BA, Martin SF. Evolution of a strategy for preparing bioactive small molecules by sequential multicomponent assembly processes, cyclizations, and diversification. Org Biomol Chem. 2014; 12:7659–7672. [PubMed: 25135846]
Sahn JJ, Hodges TR, Chan JZ, Martin SF. Norbenzomorphan Framework as a Novel Scaffold for Generating Sigma 2 Subtype-Selective Ligands. ChemMedChem. 2016; 11(6)
Sahn JJ, Martin SF. Expedient synthesis of norbenzomorphan library via multicomponent assembly process coupled with ring-closing reactions. ACS Comb Sci. 2012; 14:496–502. [PubMed: 22857149]
Yi et al. Page 17
J Neurochem. Author manuscript; available in PMC 2017 February 16.
Author M
anuscriptA
uthor Manuscript
Author M
anuscriptA
uthor Manuscript
Schmidt HR, Zheng S, Gurpinar E, Koehl A, Manglik A, Kruse AC. Crystal structure of the human sigma1 receptor. Nature. 2016; 532:527–530. [PubMed: 27042935]
Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008; 3:1101–1108. [PubMed: 18546601]
Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci. 2007; 27:2866–2875. [PubMed: 17360908]
Simonsen KT, Gallego SF, Faergeman NJ, Kallipolitis BH. Strength in numbers: "Omics" studies of C. elegans innate immunity. Virulence. 2012; 3:477–484. [PubMed: 23076279]
Sly LM, Krzesicki RF, Brashler JR, Buhl AE, McKinley DD, Carter DB, Chin JE. Endogenous brain cytokine mRNA and inflammatory responses to lipopolysaccharide are elevated in the Tg2576 transgenic mouse model of Alzheimer's disease. Brain Res Bull. 2001; 56:581–588. [PubMed: 11786245]
Sonnhammer EL, Durbin R. Analysis of protein domain families in Caenorhabditis elegans. Genomics. 1997; 46:200–216. [PubMed: 9417907]
Su TP, Hayashi T, Maurice T, Buch S, Ruoho AE. The sigma-1 receptor chaperone as an inter-organelle signaling modulator. Trends Pharmacol Sci. 2010; 31:557–566. [PubMed: 20869780]
Su TP, Su TC, Nakamura Y, Tsai SY. The Sigma-1 Receptor as a Pluripotent Modulator in Living Systems. Trends Pharmacol Sci. 2016; 37:262–278. [PubMed: 26869505]
Vilner BJ, Bowen WD. Modulation of cellular calcium by sigma-2 receptors: release from intracellular stores in human SK-N-SH neuroblastoma cells. J Pharmacol Exp Ther. 2000; 292:900–911. [PubMed: 10688603]
Xu J, Zeng C, Chu W, et al. Identification of the PGRMC1 protein complex as the putative sigma-2 receptor binding site. Nat Commun. 2011; 2:380. [PubMed: 21730960]
Zar, JH. Biostatistical analysis. Upper Saddle River, N.J.: Prentice Hall; 1999.
Zhang H, Liu J, Sun S, Pchitskaya E, Popugaeva E, Bezprozvanny I. Calcium signaling, excitability, and synaptic plasticity defects in a mouse model of Alzheimer's disease. J Alzheimers Dis. 2015; 45:561–580. [PubMed: 25589721]
Yi et al. Page 18
J Neurochem. Author manuscript; available in PMC 2017 February 16.
Author M
anuscriptA
uthor Manuscript
Author M
anuscriptA
uthor Manuscript
Figure 1. Sig2R binding ligands with neuromodulatory (JVW-1009, SAS-0132, DKR-1005, and DKR-1051) and cognition enhancing activity (SAS-0132).
Yi et al. Page 19
J Neurochem. Author manuscript; available in PMC 2017 February 16.
Author M
anuscriptA
uthor Manuscript
Author M
anuscriptA
uthor Manuscript
Figure 2. Effects of the Sig2R ligands on intracellular calcium in SK-N-SH neuroblastoma cells(A) DKR-1051 induces concentration-dependent increases in intracellular calcium (### p <
0.001 versus DKR-1051 (0 µM), one-way ANOVA followed by Dunnett’s multiple
comparison test). (B) SAS-0132 does not induce significant increases in intracellular
calcium up to 30 µM, but produces a significant calcium response at 100 µM (### p < 0.001
versus SAS-0132 (0 µM), one-way ANOVA followed by Dunnett’s multiple comparison
test). (C) SAS-0132 attenuated the calcium response induced by DRK-1051 (### p < 0.001
versus DKR-1051 (0 µM); * p < 0.05 and ** p < 0.01 versus DKR-1051 (100 µM), one-way
ANOVA followed by Dunnett’s multiple comparison test). Data are presented as mean ±
SEM from 3–4 independent experiments performed in duplicate or triplicate.
Yi et al. Page 20
J Neurochem. Author manuscript; available in PMC 2017 February 16.
Author M
anuscriptA
uthor Manuscript
Author M
anuscriptA
uthor Manuscript
Figure 3. Neuroprotective effects of SAS-0132(A) In our C. elegans model of neurodegeneration, transgenic worms carry a single copy
insertion of human amyloid precursor protein (SC_APP). VC class cholinergic neurons
express GFP. (B) Representative fluorescence and phase contrast images of VC4 and 5
neurons in transgenic SC_APP C. elegans (on day 1 and 3 of adulthood). (C) Transgenic C. elegans expressing SC_APP display age-dependent degeneration of VC4 and 5 compared to
wild-type (WT) controls (*** p < 0.001 versus WT control, planned comparisons with
Fisher’s exact test, n=60–128). (D) Neurodegeneration in these transgenic C. elegans is
significantly diminished with two different null alleles of vem-1, an ortholog of PGRMC1
(** p < 0.01 and *** p < 0.001 versus transgenic hAPP animals with WT PGRMC1,
planned comparisons with Fisher’s exact test, n=194–230) (E) DKR-1005 exacerbates the
neurodegeneration shown in the transgenic SC_APP worm, while JVW-1009 and SAS-0132
decrease the neurodegeneration in the transgenic SC_APP worm (** p < 0.01 versus vehicle
group, planned comparisons with Fisher’s exact test, n=110–378) (F) Knockdown of
PGRMC1 or pharmacological modulation of Sig2R/PGRMC1 with JVW-1009 ameliorates
the neurodegeneration shown in the transgenic C. elegans (*** p < 0.001 versus
Yi et al. Page 21
J Neurochem. Author manuscript; available in PMC 2017 February 16.
Author M
anuscriptA
uthor Manuscript
Author M
anuscriptA
uthor Manuscript
JVW-1009(−)/PGRMC1 RNAi (−) group, planned comparisons with Fisher’s exact test,
n=110–142). JVW-1009 provides no further effects in animals with reduced PGRMC1
expression. (G) Knockdown of PGRMC1 or pharmacological modulation of Sig2R/
PGRMC1 with SAS-0132 ameliorates the neurodegeneration shown in the transgenic C. elegans (** p < 0.01 versus SAS-0132(−)/PGRMC1 RNAi (−) group, planned comparisons
with Fisher’s exact test, n=130–138). SAS-0132 provides no further effects in animals with
reduced PGRMC1 expression.
Yi et al. Page 22
J Neurochem. Author manuscript; available in PMC 2017 February 16.
Author M
anuscriptA
uthor Manuscript
Author M
anuscriptA
uthor Manuscript
Figure 4. Pharmacokinetics of SAS-0132(A) Plasma concentration of SAS-0132 in mice plasma collected over 3 h post-dose after a
single injection of SAS-0132 (10 mg/kg) via intravenous (IV), subcutaneous (SC), and oral
(PO) administration (n = 3 per route). (B) Bioavailability of SAS-0132 by SC and PO dosing
(n = 3 per route). (C,D) Brain concentration and brain/plasma ratio of SAS-0132 3 h after
the administration of SAS-0132 (n = 3 per route). Data are represented as mean ±SEM.
Yi et al. Page 23
J Neurochem. Author manuscript; available in PMC 2017 February 16.
Author M
anuscriptA
uthor Manuscript
Author M
anuscriptA
uthor Manuscript
Figure 5. Effects of SAS-0132 on cognitive functions in the chronic daily dosing study(A) In the sociability test, vehicle-treated wild-type (WT) mice explored a cup containing a
C57Bl/6 mouse more than an empty cup, showing normal sociability. APPLond/Swe+ mice
treated with vehicle showed lack of sociability, while APPLond/Swe+ mice treated with SAS-
0132 (10 mg/kg) showed normal sociability (t-test, mouse versus empty cup, *p < 0.05, ** p < 0.01, n =9–12 per group).(B) In the Y-maze, WT mice showed spontaneous alternation
behavior, indicating a normal spatial memory. The vehicle-treated APPLond/Swe+ mice
showed impaired spontaneous alternation performance. The APPLond/Swe+ mice treated with
SAS-0132 (10 mg/kg) showed spontaneous alteration behavior to a level comparable to the
WT mice (One-sample t-test vs 50% theoretical mean, *p < 0.05, ** p < 0.01, *** p <
0.001, n=9–12 per group). The number of total entries were not significantly different
among groups (one-way ANOVA). Data represent mean ± SEM.. Wild-type, WT;
APPLond/Swe+, APP.
Yi et al. Page 24
J Neurochem. Author manuscript; available in PMC 2017 February 16.
Author M
anuscriptA
uthor Manuscript
Author M
anuscriptA
uthor Manuscript
Figure 6. Effects of SAS-0132 on cognitive function in the chronic daily dosing dose-response study(A) In the social recognition test, only the APPLond/Swe+ mice group treated with 3 mg/kg of
SAS-0132 distinguished between a novel and familiar mouse, preferring a novel mouse (t-
test, familiar versus novel, ***p < 0.001, n = 3 – 5 per group). (B) In the Y-maze test, the
APPLond/Swe+ mice showed impaired spontaneous alternation behavior, which was restored
by chronic administration of SAS-0132. Both wild-type (WT) and APPLond/Swe+ mice dosed
with 30 mg/kg showed impaired spontaneous alternation behavior (One-sample t-test vs
50% theoretical mean, *p < 0.05, ** p < 0.01, n = 3 – 5 per group). The number of total
Yi et al. Page 25
J Neurochem. Author manuscript; available in PMC 2017 February 16.
Author M
anuscriptA
uthor Manuscript
Author M
anuscriptA
uthor Manuscript
entries was not significantly different among groups (One-way ANOVA). (C) WT mice
groups treated with 3 and 30 mg/kg SAS-0132 showed faster escape latency compared to
vehicle-treated WT mice during the hidden platform training (Repeated measures of
ANOVA, * p < 0.01 versus vehicle-treated WT, n = 3 – 5 per group). During the probe trial,
WT mice treated with 3 mg/kg of SAS-0132 showed target quadrant preference(t-test, target
versus non-target quadrant, * p < 0.01), while the other three groups did not show this
preference (n = 3 – 5 per group). (D) APPLond/Swe+ mice showed signs of learning as
indicated by preference for the target over the non-target quadrant during the probe trial,
although not significant (n = 3 – 5 per group). Three of the five mice in the 30 mg/kg
APPLond/Swe+ group did not perform the task. Thus, this group was excluded from the
analyses. (E) On the second day of the reversal learning training, WT mice treated with 10
and 30 mg/kg SAS-0132 found the escape platform significantly faster relative to vehicle-
treated WT mice (one-way ANOVA, * p < 0.05 post-hoc, n = 3 – 5 per group). During the
reversal probe trial, all WT groups showed target quadrant preference with the exception of
the 3 mg/kg dose group (paired t-test, * p < 0.05, *** p < 0.001, n = 3 – 5 per group). (F)
The reversal learning training revealed no main effect of drug on learning in APPLond/Swe+
mice (repeated measures of ANOVA), although a non-significant decreased escape latency
was observed for APPLond/Swe+ mice treated with 3 and 10 mg/kg SAS-0132 compared to
the vehicle-treated APPLond/Swe+ mice (n = 3 – 5 per group). During the reversal probe trial,
APPLond/Swe+ vehicle-treated mice did not show target quadrant preference. APPLond/Swe+
mice treated with 10 mg/kg SAS-0132 showed preference for the target over the non-target
quadrant (paired t-test, ** p < 0.01, n = 3 – 5 per group). Three of five mice in the 30 mg/kg
APPLond/Swe+ group did not pass the swimming performance criteria. Thus, this group was
excluded from the analyses. Three additional mice in 3 other groups (WT-vehicle,
APPLond/Swe+-3 and-10 mg/kg), were also excluded for the same reason. Data represent
mean ± SEM. Wild-type, WT; APPLond/Swe+, APP.
Yi et al. Page 26
J Neurochem. Author manuscript; available in PMC 2017 February 16.
Author M
anuscriptA
uthor Manuscript
Author M
anuscriptA
uthor Manuscript
Figure 7. Effects of SAS-0132 on neuroinflammation in the chronic daily dosing dose-response studyTNFα, CD14, and IL1β expression was elevated in the vehicle-treated APPLond/Swe+ mice
compared to wild-type (WT) counterparts, although not significantly. SAS-0132 treatment
attenuated increases in IL1β expression. Bar graphs depict mRNA expression in cortical
tissue from WT and APPLond/Swe+ mice. mRNA expression was normalized relative to
vehicle-treated WT mice for each gene. Data represent mean ± SEM. n= 3–5 per group.
Wild-type, WT; APPLond/Swe+, APP.
Yi et al. Page 27
J Neurochem. Author manuscript; available in PMC 2017 February 16.
Author M
anuscriptA
uthor Manuscript
Author M
anuscriptA
uthor Manuscript